Refers to benzilindazoles substituted derivative compounds of formula (i) wherein R1 is H, alkyl or Halogen (C1 - C3) R2 and R3 are each h, halogeno, cyano, haloalquilo (C1 - C6), among others R4 is H, Hydroxy, alquenilo (C2 - C6), among others R6 H, CN, alkoxy (C1 - C6), among others R7 is H, alkyd ILO (C1 - C6), haloalquilo (C1 - C6), among others R8 is H, halogen, alkyl (C1 - C6)Among others n is 0 to 3 M is 0 to 4. Preferred compounds are: 2 - [1 - (6 - Chloro - 2-fluoro-3 - metilbencil) - 1H - indazol IL - 3 - 5 - methoxy] - N - (pyridin-4-yl) pyrimidin-2-yl) - Amine 2 - [1 - (6 - Chloro - fluoro - 2 - 3 - metoxibencil) - 1H - indazol il - 3 - 5 - methoxy] - N - (pyridin-4-yl) Amine pyrimidine - 4 5 - methoxy - 2 - {[1 - 3 - 5 - methyl - 3 - 1,2,4 - Oxadiazoles - il) benzyl] - 1H indazol - il - 3} - n - (pyridin-4-yl) pyrimidin-2-yl) - Amine among others.It also relates to a process for its production and a Pharmaceutical composition. These compounds are inhibitors of the kinase BUB1 being useful for the treatment of cervical tumor, Breast, melanoma, metastasisSE REFIERE A COMPUESTOS DERIVADOS DE BENZILINDAZOLES SUSTITUIDOS DE FORMULA (I) DONDE R1 ES H, HALOGENO O ALQUILO(C1-C3) R2 Y R3 SON CADA UNO H, HALOGENO, CIANO, HALOALQUILO(C1-C6), ENTRE OTROS R4 ES H, HIDROXI, ALQUENILO(C2-C6), ENTRE OTROS R6 ES H, CN, ALCOXI(C1-C6), ENTRE OTROS R7 ES H, ALQUILO(C1-C6), HALOALQUILO(C1-C6), ENTRE OTROS R8 ES H, HALOGENO, ALQUILO(C1-C6), ENTRE OTROS n ES DE 0 A 3 m ES DE 0 A 4. SON COMPUESTOS PREFERIDOS: 2-[1-(6-CLORO-2-FLUORO-3-METILBENCIL)-1H-INDAZOL-3-IL]-5-METOXI-N-(PIRIDIN-4-IL)PIRIMIDIN-4-AMINA 2-[1-(6-CLORO-2-FLUORO-3-METOXIBENCIL)-1H-INDAZOL-3-IL]-5-METOXI-N-(PIRIDIN-4-IL)PIRIMIDIN-4-AMINA 5-METOXI-2-{1-[3-(5-METIL-1,2,4-OXADIAZOL-3-IL)BENCIL]-1H-INDAZOL-3-IL}-N-(PIRIDIN-4-IL)PIRIMIDIN-4-AMINA ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO PARA SU OBTENCION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA BUB1 SIENDO UTILES PARA EL T
